StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.\DE gross margin

Gross margin is gross profit as a percentage of revenue.

Viridian Therapeutics, Inc.\DE's gross margin for the twelve months ending Dec 31, 2016 was 26.7%. For fiscal 2016 it was 26.7%, against 2.6% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2016Dec 31, 201626.7%+24.1
FY2015Dec 31, 20152.6%−45.5
FY2014Dec 31, 201448.1%−1.3
FY2013Dec 31, 201349.4%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2016Dec 31, 2016-36.0%–
Q3 FY2016Sep 30, 201636.0%–

More Viridian Therapeutics, Inc.\DE figures

See a number that looks wrong?